This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

What Influences Patient Outcome in Obstructive Airway Disease?

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Brian J Lipworth, University of Dundee
ClinicalTrials.gov Identifier:
NCT01221480
First received: October 14, 2010
Last updated: November 30, 2016
Last verified: November 2016
  Purpose
The aim of this observational study is to utilise the established record linkage data available in Tayside to investigate hospital admissions, exacerbations and mortality in COPD.

Condition
COPD

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Beta-Blockers Reduce Mortality and Exacerbations When Added to Stepwise Inhaled Therapy for COPD Without Adverse Effects on Lung Function.

Resource links provided by NLM:


Further study details as provided by Brian J Lipworth, University of Dundee:

Primary Outcome Measures:
  • All-cause Mortality

Secondary Outcome Measures:
  • Hospital Admissions
  • COPD exacerbations

Enrollment: 5977
Study Start Date: August 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Beta Blocker Use
No beta blocker use

  Eligibility

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
COPD patients within NHS Tayside, UK
Criteria

Inclusion Criteria:

  • Data collected through TARDIS database

Exclusion Criteria:

  • History of asthma or malignancy. Less than 50 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Brian J Lipworth, Professor (Clinical) Airway allergy and COPD, University of Dundee
ClinicalTrials.gov Identifier: NCT01221480     History of Changes
Other Study ID Numbers: SHO002
Study First Received: October 14, 2010
Last Updated: November 30, 2016

Additional relevant MeSH terms:
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017